[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100389154":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":19,"locations":25,"responsibleParty":44,"collaborators":7,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":7,"enrollmentInfo":56,"targetDuration":59,"studyType":60,"phases":7,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","OTHER_GOV",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Anticoagulants","oral anticoagulants, dual or triple antithrombotic theraphy",[14],"antiplatelets",[16],{"name":17,"affiliation":5,"role":18},"Elizaveta Panchenko, PhD","PRINCIPAL_INVESTIGATOR",[20],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"Ekaterina Kropacheva, PhD","CONTACT","+79166760695","katekrab@list.ru",[26],{"facility":5,"status":27,"city":28,"state":7,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Moscow","121552","Russia","RU",{"type":33,"coordinates":34},"Point",[35,36],37.61781,55.75204,{"lat":36,"lon":35},[39,40,42],{"name":17,"role":18,"phone":7,"phoneExt":7,"email":7},{"name":21,"role":41,"phone":7,"phoneExt":7,"email":7},"SUB_INVESTIGATOR",{"name":43,"role":41,"phone":7,"phoneExt":7,"email":7},"Oksana Zemlyanskaya, PhD",{"type":45,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100389154","registry-of-long-term-antithrombotic-therapy-2-100389154",false,"NCT04347187","REGistry of Long-term AnTithrombotic TherApy-2","Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Atrial Fibrillation","REGATTA-2","Inclusion Criteria:\n\n* Documented atrial fibrillation with CHA2DS2VASC \\> 1\n\nExclusion Criteria:\n\n* Subjects who are unwilling or unable to provide informed consent. ACS within 12 months before inclusion Severe CHF (NYHA IV) Stroke within 6 months before inclusion Severe liver or muscle disease Severe kidney disease \u002F renal failure with creatinine \\> 3 mg\u002Fdl Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention","ALL","18 Years",{"count":57,"type":58},2000,"ESTIMATED","5 Years","OBSERVATIONAL","To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation",[63],"Atrial Fibrillation",[65],"atrial fibrillation, coronary artery disease","2026-04-27",{"date":68,"type":69},"2026-05-01","ACTUAL",{"date":71,"type":69},"2015-01-15",{"date":73,"type":58},"2026-12-31",{"name":5,"class":6},1]